Compound: Ambrisentan
SMILES: O=C(O)[C@@H](Oc1nc(cc(n1)C)C)C(OC)(c2ccccc2)c3ccccc3
InChIKey: OUJTZYPIHDYQMC-LJQANCHMSA-N
Synonyms: Ambrisentan, 177036-94-1, Letairis, Volibris, LU-208075, BSF-208075, HW6NV07QEC, DTXSID4046282, GSK1325760A, GSK-1325760A, GSK1325760, GSK-1325760, DTXCID2026282, (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid, (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid, ambrisentanum, Pulmonext, (S)-ambrisentan, (+)-ambrisentan, (-)-ambrisentan, (2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, BSF208075, RefChem:56361, C02KX02, GSK 1325760A, GSK 1325760, 658-059-9, (S)-2-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid, (S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid, BSF 208075, (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid, LU 208075, C22H22N2O4, MFCD09842330, CHEMBL1111, Benzenepropanoic acid, alpha-[(4,6-dimethyl-2-pyrimidinyl)oxy]-beta-methoxy-beta-phenyl-, (alphaS)-, Ambrisentan [INN], (s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid, CAS-177036-94-1, LU208075, UNII-HW6NV07QEC, Ambrisentan [INN:BAN:JAN], Ambrisentan?, NCGC00160662-01, Letairis (TN), Volibris (TN), BSF 208075;LU 208075, Ambrisentan (Standard), Ambrisentan (JAN/INN), AMBRISENTAN [MI], AMBRISENTAN [JAN], AMBRISENTAN [VANDF], SCHEMBL3679, A1D5J, AMBRISENTAN [MART.], AMBRISENTAN [WHO-DD], AMBRISENTAN, (+)-, MLS006010218, AMBRISENTAN [EMA EPAR], GTPL3951, orb1307867, Ambrisentan - Bio-X trade mark, AMBRISENTAN [ORANGE BOOK], CHEBI:135949, OUJTZYPIHDYQMC-LJQANCHMSA-N, GLXC-04478, EX-A3315, Tox21_111967, BDBM50146710, EBC-26858, FD7219, HY-13209R, s2097, AKOS015994540, Tox21_111967_1, AC-9015, CCG-268386, CS-0447, DB06403, DE-0223, FA17344, (?S)-?-[(4,6-Dimethyl-2-pyrimidinyl)oxy]-?-methoxy-?-phenylbenzenepropanoic acid, NCGC00160662-02, NCGC00346730-01, BA164153, HY-13209, SMR004701307, A2966, SW219060-1, D07077, AB01566890_01, EN300-7368573, Q410789, BRD-K41185545-001-02-3, (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid, (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid, (S)-2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid, Ambrisentan2-(4,6-Dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid, Benzenepropanoic acid, |A-[(4,6-dimethyl-2-pyrimidinyl)oxy]-|A-methoxy-|A-phenyl-, (|AS)-
Theoretical properties:
molecular_formula: C22H22N2O4
molecular_weight: 378.4 g/mol
exact_mass: 378.15795719 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 7
heavy_atom_count: 28
topological_polar_surface_area: 81.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 165-168 °C
solubility: Ambrisentan is practically insoluble in aqueous solutions at low pH. Solubility increases at higher pH.
Descriptions:
pubchem: Ambrisentan is a diarylmethane.
chembl: AMBRISENTAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Ambrisentan, sold under the brand name Letairis among others, is a drug used for the treatment of pulmonary hypertension. It is an endothelin receptor antagonist.
The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind, multicenter trials (ARIES-1 and ARIES-2). Like all endothelin receptor antagonists, Ambrisentan is contraindicated in pregnant women as well as those who are trying to  become pregnant, due to the potential for teratogenic effects on the fetus.
Ambrisentan was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and designated an orphan drug, for the treatment of pulmonary hypertension.